close

Enter

Log in using OpenID

Insulin Biosimilars Market Will Witness a Staggering Growth During 2018-2026

embed
Biosimilar is a medicine developed on the original biological reference product. The production process of biopharmaceuticals vary from one manufacturer to another, thus every biosimilar product is unique from the other.
Insulin Biosimilars Market Will Witness a
Staggering Growth During 2018-2026
Insulin Biosimilars Market, by Biosimilar Type (Rapid-acting Biosimilars, Longacting Biosimilars, and Premixed Biosimilars), by Disease Indication Type (Type
1 Diabetes and Type 2 Diabetes), and by Geography - Size, Share, Outlook and
Opportunity Analysis 2018-2026
Biosimilar is a medicine developed on the original biological reference product. The production
process of biopharmaceuticals vary from one manufacturer to another, thus every biosimilar product is
unique from the other. Biosimilar manufactures use different culture conditions, master cell lines,
purification techniques, and raw materials. This in turn, helps meet the rising prevalence of diabetes
due to inadequate healthcare services, rising prevalence of obesity. According to 2013 American
Society For Metabolic And Bariatric Surgery report, obesity was a major independent risk factor for
developing the disease, and more than 90% of type 2 diabetics population are overweight or obese due
to growing adoption of unhealthy lifestyle. Insulin is distributed and manufactured by small number of
multinational companies in emerging economies, beyond the established biosimilar manufactures, and
a handful of small players are developing insulin manufacturing capacities based on modern
biotechnological methods in turn, boosting growth of the Insulin Biosimilars Market size.
Insulin Biosimilars Market – Dynamics
Increasing number of manufacturers are developing biosimilar insulin to provide clinical aid that are
similar to current insulin analogs at the more affordable price. Moreover, the patents of several insulin
manufacturing companies are soon expected to lose patent protection, For instance, LEVEMIR an
Insulin detemir by Novo Nordisk is going to lose its patent rights in year 2019, which is influencing
numerous pharmaceutical key manufacturers to develop alternatives to patents, referred as biosimilar.
The low cost of biosimilar insulin for diabetes treatment and effectiveness is helping treat patients
suffering from diabetes mellitus. Companies are also focusing on developing medical devices that
allows for less painful and safe delivery of the biosimilar insulin treatment, which in turn, is boosting
market growth. Government agencies are focusing on the endorsement of insulin biosimilar by funding
research and development. Furthermore, rising geriatric population across the globe and increasing
demand for rapid-acting insulin analogues is boosting growth of the insulin biosimilar market. For
instance, according to a consensus report published in 2012 American Diabetes Association, showed
over 25% of the U.S. population aged ≥65 years suffered from diabetes.
Insulin Biosimilars Market - Taxonomy
On the basis of biosimilar type, the global insulin biosimilars market is segmented into:
•Rapid Acting Biosimilars
•Long Acting Biosimilars
•Premixed Biosimilars
On the basis of disease indication type, the global insulin biosimilars market is segmented into:
•Type 1 Diabetes
•Type 2 Diabetes
Insulin Biosimilars Market – Competitive Insights
The key players operating in the global insulin biosimilars market includes Boehringer Ingelheim,
Pfizer Inc., Biocon, Merck & Co., Mylan N.V., Eli Lilly & Co., Wockhardt Limited, NOVO Nordisk
A/S, Sanofi S.A., Ypsomed AG and others Key players are engaged in developing new technologies
and collaborations in order to retain dominant position in the market. For instance on 2018 Sandoz, a
Norartis division and Asia’s premier biopharmaceutical company, Biocon announced exclusive global
collaboration for next generation biosimilars.
Ask For Sample Copy Of This Business Research Report :
https://www.coherentmarketinsights.com/insight/request-sample/1750
Insulin Biosimilars Market – Regional Insights
On the basis of region, the global insulin biosimilars market is segmented into North America, Europe,
Latin America, Asia Pacific, Middle East, and Africa. North America leads the global insulin biosimilar
market, owing to rising geriatric population and high prevalence of diabetes-related disorders in the
region. Moreover, government support for diabetes-free states is accelerating growth of the insulin
biosimilar market in North America. For instance, Centers for Disease Control and Prevention (CDC)
runs a National Diabetes Prevention Program in various U.S states.
The market in Europe accounts for the second-leading share in the global market, mainly due to
increasing number of primary approvals for biosimilar insulin. For example, European Commission
(EC) approved Mylan and Biocon’s biosimilar insulin—Glargine—for treating diabetes on March 27,
2018. Asia Pacific market is expected to gain significant traction over the forecast period due to
increasing government support, improving healthcare conditions and growing diabetes incidence in the
region. For instance, 2011 World Health Organization report shows that diabetes deaths will double
between 20011 and 2030.
About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready
syndicated research reports, custom market analysis, consulting services, and competitive analysis
through various recommendations related to emerging market trends, technologies, and potential
absolute dollar opportunity.
Contact Us:
Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Tel: +1–206–701–6702
Email: [email protected]
Author
ravikiran
ravikiran252   documents Email
Document
Category
Health and Medicine
Views
2
File Size
387 KB
Tags
market
1/--pages
Report inappropriate content